Home
About Us
In this Issue
Previous Issue
Editorial Board
How to Contribute
Advertise with Us
Editorial Calendar
Subcribe Now
Global Healthcare Releases provided by Business Wire

 The Publication & Databases on Biotechnology in the Asia Pacific
 
 More free   feature articles 
  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

INSIDE INDUSTRY
Clinical Network Services acquires New Zealand partner BELTAS’ business assets
Clinical Network Services (CNS), an Australian based CRO offering integrated development services in the planning, implementation and delivery of Phase I and II trials announced that it has acquired the business assets of its erstwhile New Zealand partner BELTAS, a CRO based in Auckland.

The acquisition of BELTAS’ business officially completed with BELTAS contracts and all clinical staff transferring to CNS.  BELTAS will continue to provide GCP training in New Zealand.

Russell Neal, Managing Director of CNS commented: “2012 has been a tremendous year for CNS and has seen us grow significantly over the last 12 months, expand our regional CRA base so we can better service local sites in Perth and Melbourne as well as further bed down our BioDesk services. This acquisition continues our goal of widening our capabilities across Australia and New Zealand and by bringing together these two highly skilled clinical teams with years of collective experience we are able to offer our clients a truly regional solution.

At the same time, CNS announced that its BioDesk service launched a year ago at the Genesis conference in London, had been a huge success and already gaining a very positive international reputation.  BioDesk is an intelligent product development and regulatory affairs service designed for biotech companies planning to enter the clinic faster by virtue of creating and managing a pre-clinical program that encompasses a globalized regulatory perspective whilst leveraging unique regional advantages.

Mark Reid, Associate Director, BioDesk & Regulatory Affairs, added: “2012 has been a remarkable year with BioDesk performing well beyond our expectations. There is an obvious need for biotechnology companies to obtain expert support in making the transition from ‘bench’ to the clinic and BioDesk aims to provide this capability – particularly for companies looking to trial their products in Australia or New Zealand.”

Click here for the complete issue.


About Us | How to Contribute | How to Advertise With Us | Contact Us |

"The views expressed here does not necessarily reflect the views of Asia Pacific Biotech News or its staff."
Copyright © 2014 World Scientific Publishing Co. All rights reserved.